nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—CYP1A1—lung cancer	0.388	1	CbGaD
Isoprenaline—CYP1A1—Gefitinib—lung cancer	0.047	0.628	CbGbCtD
Isoprenaline—CYP1A1—Erlotinib—lung cancer	0.0278	0.372	CbGbCtD
Isoprenaline—PIK3R3—mammary gland—lung cancer	0.00937	0.103	CbGeAlD
Isoprenaline—PIK3R1—mammary gland—lung cancer	0.00801	0.0881	CbGeAlD
Isoprenaline—ADRBK1—mammary gland—lung cancer	0.00554	0.0609	CbGeAlD
Isoprenaline—MAPK1—mammary gland—lung cancer	0.00546	0.06	CbGeAlD
Isoprenaline—PIK3R3—bronchus—lung cancer	0.00514	0.0565	CbGeAlD
Isoprenaline—PIK3R1—bronchus—lung cancer	0.00439	0.0483	CbGeAlD
Isoprenaline—PIK3R1—trachea—lung cancer	0.00394	0.0434	CbGeAlD
Isoprenaline—PIK3R1—cardiac atrium—lung cancer	0.0037	0.0407	CbGeAlD
Isoprenaline—ADRBK1—respiratory system—lung cancer	0.00369	0.0406	CbGeAlD
Isoprenaline—MAPK1—respiratory system—lung cancer	0.00364	0.04	CbGeAlD
Isoprenaline—PIK3R3—lung—lung cancer	0.00332	0.0365	CbGeAlD
Isoprenaline—PIK3R1—bone marrow—lung cancer	0.00313	0.0344	CbGeAlD
Isoprenaline—MAPK1—epithelium—lung cancer	0.00304	0.0334	CbGeAlD
Isoprenaline—PIK3R1—lung—lung cancer	0.00283	0.0312	CbGeAlD
Isoprenaline—MAPK1—cardiac atrium—lung cancer	0.00253	0.0278	CbGeAlD
Isoprenaline—Tachyarrhythmia—Doxorubicin—lung cancer	0.00236	0.029	CcSEcCtD
Isoprenaline—Pallor—Teniposide—lung cancer	0.0023	0.0283	CcSEcCtD
Isoprenaline—PIK3R3—lymph node—lung cancer	0.00227	0.025	CbGeAlD
Isoprenaline—Masoprocol—IGF1R—lung cancer	0.00217	0.618	CrCbGaD
Isoprenaline—ADRBK1—bone marrow—lung cancer	0.00216	0.0238	CbGeAlD
Isoprenaline—MAPK1—bone marrow—lung cancer	0.00213	0.0235	CbGeAlD
Isoprenaline—ADRBK1—lung—lung cancer	0.00196	0.0216	CbGeAlD
Isoprenaline—PIK3R1—lymph node—lung cancer	0.00194	0.0213	CbGeAlD
Isoprenaline—MAPK1—lung—lung cancer	0.00193	0.0212	CbGeAlD
Isoprenaline—Angina pectoris—Pemetrexed—lung cancer	0.00144	0.0177	CcSEcCtD
Isoprenaline—ADRBK1—lymph node—lung cancer	0.00134	0.0147	CbGeAlD
Isoprenaline—MAPK1—lymph node—lung cancer	0.00132	0.0145	CbGeAlD
Isoprenaline—ADRB1—bronchus—lung cancer	0.00127	0.014	CbGeAlD
Isoprenaline—Bronchospasm—Teniposide—lung cancer	0.00118	0.0145	CcSEcCtD
Isoprenaline—Arrhythmia—Crizotinib—lung cancer	0.00116	0.0142	CcSEcCtD
Isoprenaline—Pulmonary oedema—Vinorelbine—lung cancer	0.00108	0.0132	CcSEcCtD
Isoprenaline—ADRB1—cardiac atrium—lung cancer	0.00107	0.0118	CbGeAlD
Isoprenaline—Vision blurred—Crizotinib—lung cancer	0.00106	0.0131	CcSEcCtD
Isoprenaline—Arrhythmia—Pemetrexed—lung cancer	0.00106	0.013	CcSEcCtD
Isoprenaline—Arrhythmia—Gefitinib—lung cancer	0.00105	0.0129	CcSEcCtD
Isoprenaline—Sweating—Teniposide—lung cancer	0.00102	0.0126	CcSEcCtD
Isoprenaline—CYP1A1—respiratory system—lung cancer	0.000996	0.011	CbGeAlD
Isoprenaline—Cardiac arrest—Topotecan—lung cancer	0.000976	0.012	CcSEcCtD
Isoprenaline—Angina pectoris—Vinblastine—lung cancer	0.000889	0.0109	CcSEcCtD
Isoprenaline—Flushing—Teniposide—lung cancer	0.000889	0.0109	CcSEcCtD
Isoprenaline—Hypertension—Pemetrexed—lung cancer	0.000888	0.0109	CcSEcCtD
Isoprenaline—Pulmonary oedema—Gemcitabine—lung cancer	0.000865	0.0106	CcSEcCtD
Isoprenaline—Arrhythmia—Teniposide—lung cancer	0.000855	0.0105	CcSEcCtD
Isoprenaline—CYP1A1—epithelium—lung cancer	0.000832	0.00916	CbGeAlD
Isoprenaline—ADRB1—lung—lung cancer	0.00082	0.00902	CbGeAlD
Isoprenaline—CYP1A1—bronchus—lung cancer	0.00082	0.00902	CbGeAlD
Isoprenaline—Dyspnoea—Crizotinib—lung cancer	0.000819	0.0101	CcSEcCtD
Isoprenaline—Hypotension—Gefitinib—lung cancer	0.00078	0.00959	CcSEcCtD
Isoprenaline—Sweating—Topotecan—lung cancer	0.000758	0.00932	CcSEcCtD
Isoprenaline—Dyspnoea—Pemetrexed—lung cancer	0.000749	0.00921	CcSEcCtD
Isoprenaline—Bronchospasm—Vinorelbine—lung cancer	0.000746	0.00918	CcSEcCtD
Isoprenaline—Dyspnoea—Gefitinib—lung cancer	0.000744	0.00915	CcSEcCtD
Isoprenaline—Angina pectoris—Vinorelbine—lung cancer	0.000739	0.00909	CcSEcCtD
Isoprenaline—CYP1A1—trachea—lung cancer	0.000736	0.0081	CbGeAlD
Isoprenaline—Hypertension—Teniposide—lung cancer	0.00072	0.00885	CcSEcCtD
Isoprenaline—CYP1A1—cardiac atrium—lung cancer	0.000692	0.00761	CbGeAlD
Isoprenaline—Cardiac arrest—Irinotecan—lung cancer	0.000688	0.00846	CcSEcCtD
Isoprenaline—Arformoterol—CYP2A6—lung cancer	0.000672	0.191	CrCbGaD
Isoprenaline—Formoterol—CYP2A6—lung cancer	0.000672	0.191	CrCbGaD
Isoprenaline—Tachycardia—Teniposide—lung cancer	0.000664	0.00817	CcSEcCtD
Isoprenaline—Asthenia—Crizotinib—lung cancer	0.000659	0.00811	CcSEcCtD
Isoprenaline—Hyperhidrosis—Teniposide—lung cancer	0.000658	0.00809	CcSEcCtD
Isoprenaline—Hypotension—Teniposide—lung cancer	0.000636	0.00782	CcSEcCtD
Isoprenaline—Arrhythmia—Erlotinib—lung cancer	0.000627	0.00772	CcSEcCtD
Isoprenaline—Pulmonary oedema—Docetaxel—lung cancer	0.000614	0.00755	CcSEcCtD
Isoprenaline—Angina pectoris—Irinotecan—lung cancer	0.000609	0.00749	CcSEcCtD
Isoprenaline—Dizziness—Crizotinib—lung cancer	0.000608	0.00747	CcSEcCtD
Isoprenaline—Dyspnoea—Teniposide—lung cancer	0.000607	0.00746	CcSEcCtD
Isoprenaline—Asthenia—Pemetrexed—lung cancer	0.000603	0.00741	CcSEcCtD
Isoprenaline—Bronchospasm—Gemcitabine—lung cancer	0.000599	0.00737	CcSEcCtD
Isoprenaline—Asthenia—Gefitinib—lung cancer	0.000599	0.00736	CcSEcCtD
Isoprenaline—Ventricular arrhythmia—Doxorubicin—lung cancer	0.000581	0.00715	CcSEcCtD
Isoprenaline—Cardiac arrest—Etoposide—lung cancer	0.000572	0.00704	CcSEcCtD
Isoprenaline—Vertigo—Vinblastine—lung cancer	0.000571	0.00703	CcSEcCtD
Isoprenaline—Flushing—Vinorelbine—lung cancer	0.000563	0.00693	CcSEcCtD
Isoprenaline—Cardiac arrest—Paclitaxel—lung cancer	0.000561	0.0069	CcSEcCtD
Isoprenaline—Dizziness—Pemetrexed—lung cancer	0.000555	0.00683	CcSEcCtD
Isoprenaline—Convulsion—Vinblastine—lung cancer	0.000551	0.00678	CcSEcCtD
Isoprenaline—Hypertension—Vinblastine—lung cancer	0.000549	0.00675	CcSEcCtD
Isoprenaline—Nausea—Crizotinib—lung cancer	0.000546	0.00671	CcSEcCtD
Isoprenaline—Arrhythmia—Vinorelbine—lung cancer	0.000542	0.00667	CcSEcCtD
Isoprenaline—Sweating—Irinotecan—lung cancer	0.000535	0.00658	CcSEcCtD
Isoprenaline—CYP1A1—lung—lung cancer	0.000529	0.00582	CbGeAlD
Isoprenaline—Sweating—Gemcitabine—lung cancer	0.000521	0.00641	CcSEcCtD
Isoprenaline—Bronchospasm—Etoposide—lung cancer	0.000512	0.0063	CcSEcCtD
Isoprenaline—Nausea—Pemetrexed—lung cancer	0.000499	0.00614	CcSEcCtD
Isoprenaline—Nausea—Gefitinib—lung cancer	0.000496	0.0061	CcSEcCtD
Isoprenaline—Asthenia—Teniposide—lung cancer	0.000488	0.006	CcSEcCtD
Isoprenaline—Hyperhidrosis—Topotecan—lung cancer	0.000487	0.006	CcSEcCtD
Isoprenaline—Vertigo—Vinorelbine—lung cancer	0.000475	0.00584	CcSEcCtD
Isoprenaline—Palpitations—Vinorelbine—lung cancer	0.000467	0.00574	CcSEcCtD
Isoprenaline—Flushing—Irinotecan—lung cancer	0.000465	0.00572	CcSEcCtD
Isoprenaline—Hypertension—Vinorelbine—lung cancer	0.000456	0.00561	CcSEcCtD
Isoprenaline—Insomnia—Erlotinib—lung cancer	0.000451	0.00555	CcSEcCtD
Isoprenaline—Dyspnoea—Topotecan—lung cancer	0.00045	0.00553	CcSEcCtD
Isoprenaline—Arrhythmia—Irinotecan—lung cancer	0.000447	0.0055	CcSEcCtD
Isoprenaline—Dyspnoea—Erlotinib—lung cancer	0.000445	0.00547	CcSEcCtD
Isoprenaline—Pulmonary oedema—Methotrexate—lung cancer	0.000442	0.00544	CcSEcCtD
Isoprenaline—Arrhythmia—Gemcitabine—lung cancer	0.000436	0.00536	CcSEcCtD
Isoprenaline—Headache—Teniposide—lung cancer	0.000426	0.00524	CcSEcCtD
Isoprenaline—Bronchospasm—Docetaxel—lung cancer	0.000425	0.00523	CcSEcCtD
Isoprenaline—Flushing—Cisplatin—lung cancer	0.000422	0.00519	CcSEcCtD
Isoprenaline—Angina pectoris—Docetaxel—lung cancer	0.000421	0.00518	CcSEcCtD
Isoprenaline—Tachycardia—Vinorelbine—lung cancer	0.000421	0.00518	CcSEcCtD
Isoprenaline—Arrhythmia—Cisplatin—lung cancer	0.000406	0.005	CcSEcCtD
Isoprenaline—Nausea—Teniposide—lung cancer	0.000404	0.00497	CcSEcCtD
Isoprenaline—Hypotension—Vinorelbine—lung cancer	0.000403	0.00496	CcSEcCtD
Isoprenaline—Vertigo—Irinotecan—lung cancer	0.000392	0.00482	CcSEcCtD
Isoprenaline—Flushing—Etoposide—lung cancer	0.000387	0.00475	CcSEcCtD
Isoprenaline—Dyspnoea—Vinorelbine—lung cancer	0.000385	0.00473	CcSEcCtD
Isoprenaline—Pulmonary oedema—Doxorubicin—lung cancer	0.000383	0.00471	CcSEcCtD
Isoprenaline—Flushing—Paclitaxel—lung cancer	0.000379	0.00466	CcSEcCtD
Isoprenaline—Hypertension—Irinotecan—lung cancer	0.000376	0.00463	CcSEcCtD
Isoprenaline—Vision blurred—Cisplatin—lung cancer	0.000373	0.00459	CcSEcCtD
Isoprenaline—Asthenia—Vinblastine—lung cancer	0.000372	0.00458	CcSEcCtD
Isoprenaline—Tremor—Cisplatin—lung cancer	0.000371	0.00456	CcSEcCtD
Isoprenaline—Hypertension—Gemcitabine—lung cancer	0.000367	0.00451	CcSEcCtD
Isoprenaline—Arrhythmia—Paclitaxel—lung cancer	0.000365	0.00449	CcSEcCtD
Isoprenaline—Asthenia—Topotecan—lung cancer	0.000362	0.00445	CcSEcCtD
Isoprenaline—CYP1A1—lymph node—lung cancer	0.000362	0.00398	CbGeAlD
Isoprenaline—Asthenia—Erlotinib—lung cancer	0.000358	0.0044	CcSEcCtD
Isoprenaline—Tension—Paclitaxel—lung cancer	0.000349	0.00429	CcSEcCtD
Isoprenaline—Nervousness—Paclitaxel—lung cancer	0.000345	0.00425	CcSEcCtD
Isoprenaline—Hyperhidrosis—Irinotecan—lung cancer	0.000344	0.00423	CcSEcCtD
Isoprenaline—Dizziness—Vinblastine—lung cancer	0.000343	0.00422	CcSEcCtD
Isoprenaline—Convulsion—Cisplatin—lung cancer	0.000343	0.00422	CcSEcCtD
Isoprenaline—Vision blurred—Paclitaxel—lung cancer	0.000335	0.00412	CcSEcCtD
Isoprenaline—Hyperhidrosis—Gemcitabine—lung cancer	0.000335	0.00412	CcSEcCtD
Isoprenaline—Dizziness—Topotecan—lung cancer	0.000333	0.0041	CcSEcCtD
Isoprenaline—Tremor—Paclitaxel—lung cancer	0.000333	0.0041	CcSEcCtD
Isoprenaline—Hypotension—Irinotecan—lung cancer	0.000332	0.00409	CcSEcCtD
Isoprenaline—Dizziness—Erlotinib—lung cancer	0.00033	0.00406	CcSEcCtD
Isoprenaline—Vertigo—Etoposide—lung cancer	0.000326	0.00401	CcSEcCtD
Isoprenaline—Headache—Vinblastine—lung cancer	0.000325	0.004	CcSEcCtD
Isoprenaline—Hypotension—Gemcitabine—lung cancer	0.000324	0.00398	CcSEcCtD
Isoprenaline—Insomnia—Irinotecan—lung cancer	0.000322	0.00396	CcSEcCtD
Isoprenaline—Flushing—Docetaxel—lung cancer	0.000321	0.00395	CcSEcCtD
Isoprenaline—Vertigo—Paclitaxel—lung cancer	0.000319	0.00393	CcSEcCtD
Isoprenaline—Dyspnoea—Irinotecan—lung cancer	0.000317	0.0039	CcSEcCtD
Isoprenaline—Headache—Topotecan—lung cancer	0.000316	0.00389	CcSEcCtD
Isoprenaline—Tachycardia—Cisplatin—lung cancer	0.000315	0.00388	CcSEcCtD
Isoprenaline—Palpitations—Paclitaxel—lung cancer	0.000314	0.00386	CcSEcCtD
Isoprenaline—Convulsion—Etoposide—lung cancer	0.000314	0.00386	CcSEcCtD
Isoprenaline—Insomnia—Gemcitabine—lung cancer	0.000313	0.00385	CcSEcCtD
Isoprenaline—Hypertension—Etoposide—lung cancer	0.000313	0.00385	CcSEcCtD
Isoprenaline—Headache—Erlotinib—lung cancer	0.000313	0.00384	CcSEcCtD
Isoprenaline—Hyperhidrosis—Cisplatin—lung cancer	0.000312	0.00384	CcSEcCtD
Isoprenaline—Asthenia—Vinorelbine—lung cancer	0.000309	0.00381	CcSEcCtD
Isoprenaline—Arrhythmia—Docetaxel—lung cancer	0.000309	0.0038	CcSEcCtD
Isoprenaline—Dyspnoea—Gemcitabine—lung cancer	0.000309	0.0038	CcSEcCtD
Isoprenaline—Nausea—Vinblastine—lung cancer	0.000308	0.00379	CcSEcCtD
Isoprenaline—Convulsion—Paclitaxel—lung cancer	0.000308	0.00379	CcSEcCtD
Isoprenaline—Hypertension—Paclitaxel—lung cancer	0.000307	0.00377	CcSEcCtD
Isoprenaline—Hypotension—Cisplatin—lung cancer	0.000302	0.00371	CcSEcCtD
Isoprenaline—Nausea—Topotecan—lung cancer	0.0003	0.00368	CcSEcCtD
Isoprenaline—Cardiac arrest—Doxorubicin—lung cancer	0.000297	0.00365	CcSEcCtD
Isoprenaline—Nausea—Erlotinib—lung cancer	0.000296	0.00364	CcSEcCtD
Isoprenaline—Tachycardia—Etoposide—lung cancer	0.000289	0.00355	CcSEcCtD
Isoprenaline—Dyspnoea—Cisplatin—lung cancer	0.000288	0.00354	CcSEcCtD
Isoprenaline—Hyperhidrosis—Etoposide—lung cancer	0.000286	0.00352	CcSEcCtD
Isoprenaline—Dizziness—Vinorelbine—lung cancer	0.000285	0.00351	CcSEcCtD
Isoprenaline—Tachycardia—Paclitaxel—lung cancer	0.000283	0.00348	CcSEcCtD
Isoprenaline—Hyperhidrosis—Paclitaxel—lung cancer	0.00028	0.00345	CcSEcCtD
Isoprenaline—Hypotension—Etoposide—lung cancer	0.000277	0.0034	CcSEcCtD
Isoprenaline—Hypotension—Paclitaxel—lung cancer	0.000271	0.00333	CcSEcCtD
Isoprenaline—Headache—Vinorelbine—lung cancer	0.00027	0.00332	CcSEcCtD
Isoprenaline—Sweating—Methotrexate—lung cancer	0.000266	0.00328	CcSEcCtD
Isoprenaline—Palpitations—Docetaxel—lung cancer	0.000266	0.00327	CcSEcCtD
Isoprenaline—Dyspnoea—Etoposide—lung cancer	0.000264	0.00324	CcSEcCtD
Isoprenaline—Angina pectoris—Doxorubicin—lung cancer	0.000263	0.00323	CcSEcCtD
Isoprenaline—Insomnia—Paclitaxel—lung cancer	0.000262	0.00323	CcSEcCtD
Isoprenaline—Convulsion—Docetaxel—lung cancer	0.000261	0.00321	CcSEcCtD
Isoprenaline—Hypertension—Docetaxel—lung cancer	0.00026	0.0032	CcSEcCtD
Isoprenaline—Dyspnoea—Paclitaxel—lung cancer	0.000259	0.00318	CcSEcCtD
Isoprenaline—Nausea—Vinorelbine—lung cancer	0.000256	0.00315	CcSEcCtD
Isoprenaline—Asthenia—Irinotecan—lung cancer	0.000255	0.00314	CcSEcCtD
Isoprenaline—Asthenia—Gemcitabine—lung cancer	0.000249	0.00306	CcSEcCtD
Isoprenaline—Tachycardia—Docetaxel—lung cancer	0.00024	0.00295	CcSEcCtD
Isoprenaline—Dizziness—Irinotecan—lung cancer	0.000235	0.00289	CcSEcCtD
Isoprenaline—Asthenia—Cisplatin—lung cancer	0.000232	0.00285	CcSEcCtD
Isoprenaline—Sweating—Doxorubicin—lung cancer	0.000231	0.00284	CcSEcCtD
Isoprenaline—Hypotension—Docetaxel—lung cancer	0.00023	0.00283	CcSEcCtD
Isoprenaline—Headache—Irinotecan—lung cancer	0.000223	0.00274	CcSEcCtD
Isoprenaline—Insomnia—Docetaxel—lung cancer	0.000222	0.00274	CcSEcCtD
Isoprenaline—Dyspnoea—Docetaxel—lung cancer	0.000219	0.0027	CcSEcCtD
Isoprenaline—Headache—Gemcitabine—lung cancer	0.000217	0.00267	CcSEcCtD
Isoprenaline—Asthenia—Etoposide—lung cancer	0.000212	0.00261	CcSEcCtD
Isoprenaline—Nausea—Irinotecan—lung cancer	0.000211	0.0026	CcSEcCtD
Isoprenaline—Asthenia—Paclitaxel—lung cancer	0.000208	0.00256	CcSEcCtD
Isoprenaline—Nausea—Gemcitabine—lung cancer	0.000206	0.00253	CcSEcCtD
Isoprenaline—Vision blurred—Methotrexate—lung cancer	0.000205	0.00252	CcSEcCtD
Isoprenaline—Flushing—Doxorubicin—lung cancer	0.0002	0.00247	CcSEcCtD
Isoprenaline—Dizziness—Etoposide—lung cancer	0.000196	0.00241	CcSEcCtD
Isoprenaline—Vertigo—Methotrexate—lung cancer	0.000195	0.0024	CcSEcCtD
Isoprenaline—Arrhythmia—Doxorubicin—lung cancer	0.000193	0.00237	CcSEcCtD
Isoprenaline—Dizziness—Paclitaxel—lung cancer	0.000192	0.00236	CcSEcCtD
Isoprenaline—Nausea—Cisplatin—lung cancer	0.000192	0.00236	CcSEcCtD
Isoprenaline—Convulsion—Methotrexate—lung cancer	0.000188	0.00231	CcSEcCtD
Isoprenaline—Headache—Etoposide—lung cancer	0.000185	0.00228	CcSEcCtD
Isoprenaline—Tension—Doxorubicin—lung cancer	0.000185	0.00227	CcSEcCtD
Isoprenaline—Nervousness—Doxorubicin—lung cancer	0.000183	0.00225	CcSEcCtD
Isoprenaline—Headache—Paclitaxel—lung cancer	0.000182	0.00224	CcSEcCtD
Isoprenaline—Vision blurred—Doxorubicin—lung cancer	0.000177	0.00218	CcSEcCtD
Isoprenaline—Asthenia—Docetaxel—lung cancer	0.000176	0.00217	CcSEcCtD
Isoprenaline—Nausea—Etoposide—lung cancer	0.000176	0.00216	CcSEcCtD
Isoprenaline—Nausea—Paclitaxel—lung cancer	0.000172	0.00212	CcSEcCtD
Isoprenaline—Hyperhidrosis—Methotrexate—lung cancer	0.000171	0.00211	CcSEcCtD
Isoprenaline—Vertigo—Doxorubicin—lung cancer	0.000169	0.00208	CcSEcCtD
Isoprenaline—Palpitations—Doxorubicin—lung cancer	0.000166	0.00204	CcSEcCtD
Isoprenaline—Hypotension—Methotrexate—lung cancer	0.000166	0.00204	CcSEcCtD
Isoprenaline—Convulsion—Doxorubicin—lung cancer	0.000163	0.002	CcSEcCtD
Isoprenaline—Dizziness—Docetaxel—lung cancer	0.000163	0.002	CcSEcCtD
Isoprenaline—Hypertension—Doxorubicin—lung cancer	0.000162	0.002	CcSEcCtD
Isoprenaline—Insomnia—Methotrexate—lung cancer	0.00016	0.00197	CcSEcCtD
Isoprenaline—Dyspnoea—Methotrexate—lung cancer	0.000158	0.00194	CcSEcCtD
Isoprenaline—Headache—Docetaxel—lung cancer	0.000154	0.00189	CcSEcCtD
Isoprenaline—Tachycardia—Doxorubicin—lung cancer	0.00015	0.00184	CcSEcCtD
Isoprenaline—Hyperhidrosis—Doxorubicin—lung cancer	0.000148	0.00182	CcSEcCtD
Isoprenaline—Nausea—Docetaxel—lung cancer	0.000146	0.0018	CcSEcCtD
Isoprenaline—Hypotension—Doxorubicin—lung cancer	0.000143	0.00176	CcSEcCtD
Isoprenaline—Insomnia—Doxorubicin—lung cancer	0.000139	0.00171	CcSEcCtD
Isoprenaline—Dyspnoea—Doxorubicin—lung cancer	0.000137	0.00168	CcSEcCtD
Isoprenaline—Asthenia—Methotrexate—lung cancer	0.000127	0.00156	CcSEcCtD
Isoprenaline—Dizziness—Methotrexate—lung cancer	0.000117	0.00144	CcSEcCtD
Isoprenaline—Headache—Methotrexate—lung cancer	0.000111	0.00137	CcSEcCtD
Isoprenaline—Asthenia—Doxorubicin—lung cancer	0.00011	0.00135	CcSEcCtD
Isoprenaline—Nausea—Methotrexate—lung cancer	0.000105	0.00129	CcSEcCtD
Isoprenaline—Dizziness—Doxorubicin—lung cancer	0.000101	0.00125	CcSEcCtD
Isoprenaline—Headache—Doxorubicin—lung cancer	9.61e-05	0.00118	CcSEcCtD
Isoprenaline—Nausea—Doxorubicin—lung cancer	9.12e-05	0.00112	CcSEcCtD
Isoprenaline—ADRB3—Signaling Pathways—JUN—lung cancer	3.01e-06	8.32e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FGFR1—lung cancer	3.01e-06	8.32e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—PIK3CA—lung cancer	3e-06	8.31e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MMP9—lung cancer	3e-06	8.3e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—EGFR—lung cancer	2.99e-06	8.28e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EP300—lung cancer	2.99e-06	8.27e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—CDKN1A—lung cancer	2.99e-06	8.27e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—AKT1—lung cancer	2.98e-06	8.25e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PTEN—lung cancer	2.98e-06	8.25e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTP1—lung cancer	2.98e-06	8.23e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HIF1A—lung cancer	2.96e-06	8.19e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—EGFR—lung cancer	2.95e-06	8.15e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FGFR1—lung cancer	2.94e-06	8.14e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—MAPK3—lung cancer	2.93e-06	8.11e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MMP9—lung cancer	2.93e-06	8.1e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—CDKN1A—lung cancer	2.92e-06	8.07e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—POMC—lung cancer	2.91e-06	8.06e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PTEN—lung cancer	2.91e-06	8.05e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—AKT1—lung cancer	2.91e-06	8.05e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—SRC—lung cancer	2.91e-06	8.04e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—CDKN1A—lung cancer	2.9e-06	8.03e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HIF1A—lung cancer	2.9e-06	8.01e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CAT—lung cancer	2.9e-06	8.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PTEN—lung cancer	2.89e-06	8.01e-06	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL6—lung cancer	2.88e-06	7.98e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL6—lung cancer	2.88e-06	7.97e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—EP300—lung cancer	2.88e-06	7.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—BRAF—lung cancer	2.88e-06	7.96e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—APOA1—lung cancer	2.86e-06	7.91e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EP300—lung cancer	2.84e-06	7.87e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6R—lung cancer	2.84e-06	7.86e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—AKT1—lung cancer	2.84e-06	7.85e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CREBBP—lung cancer	2.84e-06	7.85e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KDR—lung cancer	2.83e-06	7.83e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—lung cancer	2.83e-06	7.82e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ABCB1—lung cancer	2.82e-06	7.79e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—STAT3—lung cancer	2.8e-06	7.76e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—NRAS—lung cancer	2.8e-06	7.74e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—APOA1—lung cancer	2.79e-06	7.73e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—EGFR—lung cancer	2.79e-06	7.72e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—lung cancer	2.78e-06	7.7e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—HRAS—lung cancer	2.78e-06	7.69e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EP300—lung cancer	2.77e-06	7.68e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KDR—lung cancer	2.77e-06	7.66e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—TYMS—lung cancer	2.77e-06	7.65e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—SRC—lung cancer	2.76e-06	7.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EP300—lung cancer	2.76e-06	7.64e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—GSTM1—lung cancer	2.73e-06	7.57e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MAP2K1—lung cancer	2.71e-06	7.49e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—SRC—lung cancer	2.7e-06	7.47e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—VEGFA—lung cancer	2.69e-06	7.45e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CD—lung cancer	2.69e-06	7.44e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—SRC—lung cancer	2.68e-06	7.43e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—MAPK3—lung cancer	2.68e-06	7.41e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—STAT3—lung cancer	2.67e-06	7.38e-06	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—AKT1—lung cancer	2.66e-06	7.36e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NRAS—lung cancer	2.66e-06	7.36e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IL6—lung cancer	2.66e-06	7.36e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—AKT1—lung cancer	2.66e-06	7.35e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—lung cancer	2.63e-06	7.29e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—VEGFA—lung cancer	2.63e-06	7.27e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CG—lung cancer	2.61e-06	7.22e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KIT—lung cancer	2.61e-06	7.22e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—APC—lung cancer	2.61e-06	7.22e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—NRAS—lung cancer	2.61e-06	7.22e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—STAT3—lung cancer	2.6e-06	7.2e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NRAS—lung cancer	2.6e-06	7.18e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—PIK3CA—lung cancer	2.6e-06	7.18e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—STAT3—lung cancer	2.59e-06	7.16e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NRAS—lung cancer	2.58e-06	7.14e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGF—lung cancer	2.58e-06	7.13e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ERCC2—lung cancer	2.57e-06	7.11e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—PIK3CA—lung cancer	2.56e-06	7.07e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—APC—lung cancer	2.55e-06	7.06e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CG—lung cancer	2.55e-06	7.06e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KIT—lung cancer	2.55e-06	7.06e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—NRAS—lung cancer	2.55e-06	7.06e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—EGFR—lung cancer	2.55e-06	7.05e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MAPK3—lung cancer	2.55e-06	7.05e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—AKT1—lung cancer	2.54e-06	7.02e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGF—lung cancer	2.52e-06	6.98e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PIK3CA—lung cancer	2.51e-06	6.96e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—lung cancer	2.51e-06	6.95e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—MAPK3—lung cancer	2.5e-06	6.91e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MAPK3—lung cancer	2.49e-06	6.88e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—POMC—lung cancer	2.48e-06	6.87e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—MYC—lung cancer	2.48e-06	6.86e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—lung cancer	2.47e-06	6.84e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MAPK3—lung cancer	2.47e-06	6.84e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—AKT1—lung cancer	2.45e-06	6.79e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—BRAF—lung cancer	2.45e-06	6.78e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—MAPK3—lung cancer	2.44e-06	6.76e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—POMC—lung cancer	2.43e-06	6.72e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—EGFR—lung cancer	2.42e-06	6.71e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6R—lung cancer	2.42e-06	6.7e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—PIK3CA—lung cancer	2.42e-06	6.7e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CREBBP—lung cancer	2.42e-06	6.69e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—MYC—lung cancer	2.42e-06	6.69e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MDM2—lung cancer	2.41e-06	6.67e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—lung cancer	2.41e-06	6.66e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—MYC—lung cancer	2.4e-06	6.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—RAF1—lung cancer	2.4e-06	6.65e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—HRAS—lung cancer	2.4e-06	6.65e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—BRAF—lung cancer	2.4e-06	6.64e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—EGFR—lung cancer	2.38e-06	6.58e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—ERBB2—lung cancer	2.38e-06	6.58e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6R—lung cancer	2.37e-06	6.56e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CREBBP—lung cancer	2.37e-06	6.55e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—HRAS—lung cancer	2.37e-06	6.55e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—EGFR—lung cancer	2.36e-06	6.54e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—EGFR—lung cancer	2.35e-06	6.51e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MTOR—lung cancer	2.34e-06	6.49e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CB—lung cancer	2.34e-06	6.49e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—EGFR—lung cancer	2.32e-06	6.43e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MAP2K1—lung cancer	2.31e-06	6.39e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IL6—lung cancer	2.3e-06	6.36e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CD—lung cancer	2.29e-06	6.34e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—lung cancer	2.29e-06	6.33e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—PIK3CA—lung cancer	2.27e-06	6.28e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL6—lung cancer	2.26e-06	6.26e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MAP2K1—lung cancer	2.26e-06	6.25e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CXCL8—lung cancer	2.25e-06	6.24e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—lung cancer	2.24e-06	6.21e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CD—lung cancer	2.24e-06	6.21e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—HRAS—lung cancer	2.24e-06	6.2e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—lung cancer	2.23e-06	6.18e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—APOA1—lung cancer	2.22e-06	6.15e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—lung cancer	2.22e-06	6.15e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—PIK3CA—lung cancer	2.22e-06	6.15e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—PIK3CA—lung cancer	2.21e-06	6.12e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—lung cancer	2.2e-06	6.08e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CASP3—lung cancer	2.16e-06	5.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL2—lung cancer	2.15e-06	5.96e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL6—lung cancer	2.14e-06	5.93e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.13e-06	5.89e-06	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—AKT1—lung cancer	2.12e-06	5.87e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—PIK3CA—lung cancer	2.1e-06	5.82e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CCND1—lung cancer	2.1e-06	5.81e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—JUN—lung cancer	2.09e-06	5.8e-06	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—AKT1—lung cancer	2.09e-06	5.78e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—PIK3CA—lung cancer	2.06e-06	5.71e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—AKT1—lung cancer	2.05e-06	5.69e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MDM2—lung cancer	2.05e-06	5.68e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—PIK3CA—lung cancer	2.05e-06	5.68e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—RAF1—lung cancer	2.05e-06	5.66e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—HRAS—lung cancer	2.05e-06	5.66e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PIK3CA—lung cancer	2.04e-06	5.65e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MMP9—lung cancer	2.04e-06	5.64e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—lung cancer	2.03e-06	5.63e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—CDKN1A—lung cancer	2.03e-06	5.62e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CG—lung cancer	2.03e-06	5.62e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PTEN—lung cancer	2.03e-06	5.61e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—ERBB2—lung cancer	2.03e-06	5.6e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—PIK3CA—lung cancer	2.02e-06	5.58e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MDM2—lung cancer	2.01e-06	5.56e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—RAF1—lung cancer	2e-06	5.54e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MTOR—lung cancer	2e-06	5.53e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CB—lung cancer	2e-06	5.53e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—lung cancer	1.99e-06	5.49e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—ERBB2—lung cancer	1.98e-06	5.48e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—AKT1—lung cancer	1.98e-06	5.47e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL6—lung cancer	1.96e-06	5.42e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CB—lung cancer	1.95e-06	5.41e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MTOR—lung cancer	1.95e-06	5.41e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—HRAS—lung cancer	1.95e-06	5.38e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—POMC—lung cancer	1.93e-06	5.35e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EP300—lung cancer	1.93e-06	5.35e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CXCL8—lung cancer	1.92e-06	5.31e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—HRAS—lung cancer	1.91e-06	5.28e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—HRAS—lung cancer	1.9e-06	5.26e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—HRAS—lung cancer	1.89e-06	5.23e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CREBBP—lung cancer	1.88e-06	5.21e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SRC—lung cancer	1.88e-06	5.2e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CXCL8—lung cancer	1.88e-06	5.2e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—HRAS—lung cancer	1.87e-06	5.17e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL6—lung cancer	1.86e-06	5.15e-06	CbGpPWpGaD
Isoprenaline—ADRB1—GPCR downstream signaling—AKT1—lung cancer	1.86e-06	5.13e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CASP3—lung cancer	1.84e-06	5.09e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL2—lung cancer	1.84e-06	5.08e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—VEGFA—lung cancer	1.83e-06	5.06e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL6—lung cancer	1.83e-06	5.05e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL6—lung cancer	1.82e-06	5.03e-06	CbGpPWpGaD
Isoprenaline—ADRB2—GPCR downstream signaling—AKT1—lung cancer	1.81e-06	5.02e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—STAT3—lung cancer	1.81e-06	5.01e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NRAS—lung cancer	1.81e-06	5e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IL6—lung cancer	1.81e-06	5e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—AKT1—lung cancer	1.81e-06	5e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CASP3—lung cancer	1.8e-06	4.98e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL2—lung cancer	1.8e-06	4.97e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CCND1—lung cancer	1.79e-06	4.95e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL6—lung cancer	1.79e-06	4.94e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—JUN—lung cancer	1.79e-06	4.94e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CD—lung cancer	1.78e-06	4.94e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ALB—lung cancer	1.76e-06	4.88e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CCND1—lung cancer	1.75e-06	4.84e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—JUN—lung cancer	1.75e-06	4.83e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MMP9—lung cancer	1.74e-06	4.81e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MAPK3—lung cancer	1.73e-06	4.79e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—CDKN1A—lung cancer	1.73e-06	4.79e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PTEN—lung cancer	1.73e-06	4.78e-06	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—AKT1—lung cancer	1.72e-06	4.75e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MMP9—lung cancer	1.7e-06	4.7e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—CDKN1A—lung cancer	1.69e-06	4.69e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PTEN—lung cancer	1.69e-06	4.67e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—AKT1—lung cancer	1.68e-06	4.66e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—MYC—lung cancer	1.68e-06	4.66e-06	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—AKT1—lung cancer	1.68e-06	4.64e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—AKT1—lung cancer	1.67e-06	4.61e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—AKT1—lung cancer	1.65e-06	4.56e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—EGFR—lung cancer	1.65e-06	4.56e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EP300—lung cancer	1.65e-06	4.56e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EP300—lung cancer	1.61e-06	4.46e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SRC—lung cancer	1.6e-06	4.43e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SRC—lung cancer	1.57e-06	4.34e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—VEGFA—lung cancer	1.56e-06	4.32e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—lung cancer	1.56e-06	4.31e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CB—lung cancer	1.56e-06	4.3e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—STAT3—lung cancer	1.54e-06	4.27e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTGS2—lung cancer	1.54e-06	4.27e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NRAS—lung cancer	1.54e-06	4.26e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—VEGFA—lung cancer	1.53e-06	4.22e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—STAT3—lung cancer	1.51e-06	4.18e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NRAS—lung cancer	1.51e-06	4.17e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MAPK3—lung cancer	1.48e-06	4.08e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MAPK3—lung cancer	1.44e-06	3.99e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MYC—lung cancer	1.44e-06	3.97e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PIK3CA—lung cancer	1.43e-06	3.96e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MYC—lung cancer	1.4e-06	3.88e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—EGFR—lung cancer	1.4e-06	3.88e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TP53—lung cancer	1.38e-06	3.83e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—EGFR—lung cancer	1.37e-06	3.8e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTEN—lung cancer	1.34e-06	3.72e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—lung cancer	1.33e-06	3.67e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HRAS—lung cancer	1.32e-06	3.66e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—lung cancer	1.3e-06	3.59e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—EP300—lung cancer	1.28e-06	3.55e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6—lung cancer	1.27e-06	3.5e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PIK3CA—lung cancer	1.22e-06	3.37e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PIK3CA—lung cancer	1.19e-06	3.3e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—lung cancer	1.18e-06	3.26e-06	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—AKT1—lung cancer	1.17e-06	3.23e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—lung cancer	1.15e-06	3.19e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HRAS—lung cancer	1.13e-06	3.12e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HRAS—lung cancer	1.1e-06	3.05e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6—lung cancer	1.08e-06	2.99e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6—lung cancer	1.06e-06	2.92e-06	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—AKT1—lung cancer	9.95e-07	2.75e-06	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—AKT1—lung cancer	9.74e-07	2.69e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PIK3CA—lung cancer	9.48e-07	2.62e-06	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—AKT1—lung cancer	7.75e-07	2.14e-06	CbGpPWpGaD
